Jet Bio-Filtration(SH:688026)2025-04-15 13:15Financial Performance - The company's operating revenue for 2024 reached ¥558.66 million, representing a 20.63% increase compared to ¥463.10 million in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥72.19 million, a significant increase of 107.51% from ¥34.79 million in 2023[21]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥67.75 million, up 113.15% from ¥31.78 million in 2023[21]. - The company's total assets increased by 4.67% to ¥1.70 billion at the end of 2024, compared to ¥1.63 billion at the end of 2023[21]. - Basic earnings per share for 2024 were ¥0.52, reflecting an increase of 108.00% from ¥0.25 in 2023[22]. - The company's net profit margin for the company was 12.92%, reflecting a year-on-year increase of 5.41 percentage points[33]. - The company's cash and cash equivalents decreased by 47.28% to 284,205,896.01, representing 16.70% of total assets[112]. - The company reported a significant increase in tax payable by 305.23% to 20,130,806.07, mainly due to increased income tax provisions[113]. Dividend Policy - The company plans to distribute a cash dividend of 0.73 CNY per 10 shares, totaling approximately 10,047,158.34 CNY, which represents 13.92% of the net profit attributable to shareholders[4]. - The profit distribution plan has been approved by the board and is pending approval from the shareholders' meeting[4]. - The cash dividend for 2024 represents 13.92% of the net profit attributable to shareholders, while the total dividend amount, including share repurchases, accounts for 55.47% of the net profit[168]. - The company has established a cash dividend policy prioritizing stable and continuous returns to shareholders, with a minimum distribution ratio of 10% of distributable profits[162]. Research and Development - The company has filed a total of 320 patents, including 84 invention patents, enhancing its technological influence in the life sciences sector[38]. - The R&D investment as a percentage of operating revenue decreased to 4.70% in 2024 from 6.16% in 2023, a reduction of 1.46 percentage points[22]. - Total R&D expenses decreased by 7.92% from the previous year, amounting to ¥26,250,379.03 compared to ¥28,506,821.17[67]. - The company has invested in R&D for biopharmaceuticals and vaccine development, aligning with industry trends[61]. - The company is developing a high-performance separation membrane for vaccine concentration with a total investment of ¥950,000, expected to achieve a molecular weight retention of 300kDa and a flux recovery rate of no less than 80% after cleaning[69]. Market Expansion and Sales - Overseas revenue accounted for approximately 66.13% of total revenue, with a year-on-year increase of about 46.07% in overseas self-owned brand income[34]. - The company achieved approximately 23.50% year-on-year growth in overseas revenue in 2024, driven by the ODM model and expansion into emerging markets[49]. - The company is focusing on high-throughput solutions and customized services to meet the dual demands of industrial production and innovation in the life sciences sector[51]. - The company plans to continue expanding its industrial customer base domestically, aiming for further growth in sales revenue[95]. Corporate Governance - The company does not have any special arrangements for corporate governance[7]. - The company has confirmed that all board members attended the board meeting[3]. - The board of directors has established specialized committees to ensure professional and efficient decision-making processes[133]. - The company has implemented a governance structure that operates effectively in accordance with relevant laws and regulations[133]. Risks and Challenges - The company has detailed potential risks in the annual report, which can be found in the "Management Discussion and Analysis" section[3]. - The company faces risks of significant performance decline due to market competition, policy changes, and inflation, which may lead to underutilization of capacity and operational losses[80]. - The company is exposed to raw material price volatility, particularly for key plastics derived from petroleum, which could adversely affect profitability[86]. - The domestic market is predominantly occupied by imported brands, posing challenges for the company to significantly expand its market share[83]. Employee and Management - The company has increased its R&D personnel to 134, representing 12.38% of the total workforce, up from 12.10% in the previous period[74]. - The total compensation for R&D personnel reached 18.39 million RMB, with an average salary of 137,200 RMB, an increase from 132,500 RMB in the previous period[74]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 744.77 million RMB[144]. - The company has a structured compensation policy that includes various incentive mechanisms for different employee categories, ensuring alignment with market competitiveness and internal equity[159]. Sustainability and Environmental Responsibility - The company has achieved ISO 14001 certification, demonstrating its commitment to environmental responsibility[192]. - The company has implemented measures to reduce carbon emissions, including the use of rooftop solar power systems and electric vehicles[191]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[184]. - The company invested 35.36 million yuan in environmental protection during the reporting period[182].